Heightened long-term cardiovascular risks after exacerbation of chronic obstructive pulmonary disease

被引:15
|
作者
Hawkins, Nathaniel M. [1 ,7 ]
Nordon, Clementine [2 ]
Rhodes, Kirsty [2 ]
Talukdar, Manisha [3 ]
Mcmullen, Suzanne [4 ]
Ekwaru, Paul [4 ]
Pham, Tram [4 ]
Randhawa, Arsh K. [3 ]
Sin, Don D. [5 ,6 ]
机构
[1] Univ British Columbia, Ctr Cardiovasc Innovat, Div Cardiol, Vancouver, BC, Canada
[2] AstraZeneca UK Ltd, Cambridge, England
[3] AstraZeneca Canada Inc, Mississauga, ON, Canada
[4] Medlior Hlth Outcomes Res Ltd, Calgary, AB, Canada
[5] Univ British Columbia, UBC Ctr Heart Lung Innovat, Vancouver, BC, Canada
[6] Univ British Columbia, Dept Med Respirol, Vancouver, BC, Canada
[7] Univ British Columbia, St Pauls Hosp, Cardiol, 1081 Burrard St, Vancouver, BC, Canada
关键词
Heart Failure; Arrhythmias; Cardiac; Risk Factors; HEART-FAILURE; COPD; INFLAMMATION; STROKE;
D O I
10.1136/heartjnl-2023-323487
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectiveTo examine the risk of adverse cardiovascular (CV) events following an exacerbation of chronic obstructive pulmonary disease (COPD).MethodsThis retrospective cohort study identified patients with COPD using administrative data from Alberta, Canada from 2014 to 2019. Exposure periods were 12 months following moderate or severe exacerbations; the reference period was time preceding a first exacerbation. The primary outcome was the composite of all-cause death or a first hospitalisation for acute coronary syndrome, heart failure (HF), arrhythmia or cerebral ischaemia. Time-dependent Cox regression models estimated covariate-adjusted risks associated with six exposure subperiods following exacerbation.ResultsAmong 1 42 787 patients (mean age 68.1 years and 51.7% men) 61 981 (43.4%) experienced at least one exacerbation and 34 068 (23.9%) died during median follow-up of 64 months. The primary outcome occurred in 43 564 (30.5%) patients with an incidence rate prior to exacerbation of 5.43 (95% CI 5.36 to 5.50) per 100 person-years. This increased to 95.61 per 100 person-years in the 1-7 days postexacerbation (adjusted HR 15.86, 95% CI 15.17 to 16.58) and remained increased for up to 1 year. The risk of both the composite and individual CV events was increased following either a moderate or a severe exacerbation, though greater and more prolonged following severe exacerbation. The highest magnitude of increased risk was observed for HF decompensation (1-7 days, HR 72.34, 95% CI 64.43 to 81.22).ConclusionModerate and severe COPD exacerbations are independent risk factors for adverse CV events, especially HF decompensation. The impact of optimising COPD management on CV outcomes should be evaluated.
引用
收藏
页码:702 / 709
页数:8
相关论文
共 50 条
  • [31] Midlife cardiorespiratory fitness and the long-term risk of chronic obstructive pulmonary disease
    Hansen, Gorm Mork
    Marott, Jacob Louis
    Holtermann, Andreas
    Gyntelberg, Finn
    Lange, Peter
    Jensen, Magnus T.
    THORAX, 2019, 74 (09) : 843 - 848
  • [32] Effects of Long-Term Aerobic Exercise Program in Chronic Obstructive Pulmonary Disease
    Nalbant, Ozgur
    Nur, Hakan
    Ogus, Candan
    Toraman, N. Fusun
    TURKIYE FIZIKSEL TIP VE REHABILITASYON DERGISI-TURKISH JOURNAL OF PHYSICAL MEDICINE AND REHABILITATION, 2011, 57 (01): : 8 - 13
  • [33] Long-Term Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease with Sarcopenia
    Choi, Yong Jun
    Kim, Taehee
    Park, Hye Jung
    Cho, Jae Hwa
    Byun, Min Kwang
    LIFE-BASEL, 2023, 13 (08):
  • [34] Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy
    Blasi, Francesco
    Bonardi, Daniela
    Aliberti, Stefano
    Tarsia, Paolo
    Confalonieri, Marco
    Amir, Omar
    Carone, Mauro
    Di Marco, Fabiano
    Centanni, Stefano
    Guffanti, Enrico
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2010, 23 (03) : 200 - 207
  • [35] LONG-TERM PROGNOSIS OF POLYVASCULAR PATIENTS WITH ASSOCIATED CHRONIC OBSTRUCTIVE PULMONARY DISEASE
    Manea, Paloma
    Ghiuru, Rodica
    Gavrilescu, Maria Cristina
    Munteanu, D.
    MEDICAL-SURGICAL JOURNAL-REVISTA MEDICO-CHIRURGICALA, 2012, 116 (03): : 669 - 673
  • [36] Determinants of Long-Term Persistence with Tiotropium Bromide for Chronic Obstructive Pulmonary Disease
    Tanaka, Kyuto
    Kamiishi, Nobufumi
    Miyata, Jun
    Kabata, Hiroki
    Masaki, Katsunori
    Ogura-Tomomatsu, Hiromi
    Tomomatsu, Katsuyoshi
    Suzuki, Yusuke
    Fukunaga, Koichi
    Sayama, Koichi
    Betsuyaku, Tomoko
    Asano, Koichiro
    COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2015, 12 (03) : 233 - 239
  • [37] Adherence to long-term oxygen therapy in patients with chronic obstructive pulmonary disease
    Gauthier, Amelie
    Bernard, Sarah
    Bernard, Emmanuelle
    Simard, Serge
    Maltais, Francois
    Lacasse, Yves
    CHRONIC RESPIRATORY DISEASE, 2018, 16
  • [38] Cardiovascular risk in chronic obstructive pulmonary disease
    Maclay, John D.
    McAllister, David A.
    MacNee, William
    RESPIROLOGY, 2007, 12 (05) : 634 - 641
  • [39] Frailty and Exacerbation of Chronic Obstructive Pulmonary Disease: Is There Any Association?
    Nishimura, Koichi
    Kusunose, Masaaki
    Sanda, Ryo
    Shibayama, Ayumi
    Nakayasu, Kazuhito
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2024, 19 : 1131 - 1139
  • [40] Immunodeficiency in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
    Xie, Sheling
    Wang, Kaifei
    Zhang, Wei
    Xiao, Kun
    Yan, Peng
    Li, Yanqin
    He, Wanxue
    Zhang, Yuhan
    Xie, Lixin
    INFLAMMATION, 2018, 41 (05) : 1582 - 1589